A study testing whether a new weekly shot from Washington University School of Medicine, tirzepatide, can calm gut inflammation.

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

• Subjects 18 to 80 years of age, inclusive, at the time of consent
• Confirmed diagnosis of Crohn's disease based on documented findings on endoscopy and histopathology
• Active ileal or ileocolonic inflammation on colonoscopy defined as
• Failure to respond to (primary or secondary non-response) at least 2 advanced class drugs, without evidence of immunogenicity (anti-TNFa only). Must have been at least 6 months optimized on most recent therapy without corticosteroids.
• Anti-TNF: Infliximab, Adalimumab, Certolizumab, Golimumab

Key exclusion criteria

• Age < 18 or > 80 years
• Pregnant or Breastfeeding female
• Diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, diverticular disease-associated colitis, toxic megacolon, active infectious colitis or positive test for Clostridioides Difficile toxin at screening
• BMI < 25
• Current or previous diagnosis of anorexia nervosa